AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

"We have had great momentum heading into this, and we want to be sure we're ready to continue to build upon that momentum as we exit whenever that may be," said CEO Jim Clemmer.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, and Stephen Trowbridge, Executive Vice President and Chief Financial Officer, will participate in a virtual fireside chat at the UBS Virtual Global Healthcare Conference at 9:10 a.m. ET on Monday, May 18, 2020.

"If you are interested in three quarters or four quarters, we might not be your company to invest in," CEO Jim Clemmer said. "If you are interested in three or four or five years, that's what we are building here."

AngioDynamics (ANGO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the third quarter of fiscal year 2020 before the market open on Tuesday, April 7, 2020. The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Shares of AngioDynamics (NASDAQ:ANGO) jumped over 7% after the company reported upbeat Q3 results.Quarterly Results Earnings per share fell 94.74% year over year to $0.01, which beat the estimate of ($0.03).Revenue of $69,780,000 lower by 19.18% from the same period last year, which beat the estimate of $68,550,000.Looking Ahead AngioDynamics hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: Apr 07, 2020View more earnings on ANGOTime: 10:03 PM ETWebcast URL: https://edge.media-server.com/mmc/p/cbupojapPrice Action Company's 52-week high was at $23.61Company's 52-week low was at $7.48Price action over last quarter: down 28.94%Company Description AngioDynamics Inc designs, manufactures and sells medical, surgical and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings.See more from Benzinga * Greenbrier Companies: Q2 Earnings Insights * Lindsay: Q2 Earnings Insights * 12 Energy Stocks Moving In Tuesday's Pre-Market Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Today we will run through one way of estimating the intrinsic value of AngioDynamics, Inc. (NASDAQ:ANGO) by estimating...

AngioDynamics (ANGO) fiscal third-quarter results benefit from strong growth across all businesses and higher revenues.

AngioDynamics, Inc.'s (NASDAQ:ANGO): AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical...

AngioDynamics (ANGO) delivered earnings and revenue surprises of 133.33% and 1.98%, respectively, for the quarter ended February 2020. Do the numbers hold clues to what lies ahead for the stock?

Q3 2020 AngioDynamics Inc Earnings Call

AngioDynamics (ANGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

AngioDynamics (ANGO) retains fiscal 2020 view; VA revenues soft in fiscal Q2.

NEW YORK, NY / ACCESSWIRE / April 7, 2020 / AngioDynamics, Inc. (NASDAQ:ANGO) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on April 7, 2020 at 8:00 AM ...

Q2 2020 AngioDynamics Inc Earnings Call

AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced financial results for the third quarter of fiscal year 2020, which ended February 29, 2020.

AngioDynamics (ANGO) gains from core Oncology business in the fiscal second quarter, reiterates guidance.